Physician profile
Meghan E Ferrell
NPI 1518555630
$5,794.66
in general payments reported to CMS, 2019-2025
23 companies · $1,699 in 2025
The $1,699 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.56 · 2022: $1,032 · 2023: $1,661 · 2024: $1,351 · 2025: $1,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,706 · Education: $5.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,705.71 |
| Education | $5.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $760.49 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $639.17 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $607.02 | 2022-2025 | Rexulti, Abilify Maintena, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $602.18 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $573.17 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $468.44 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $371.41 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $292.12 | 2023-2025 | Invega, Spravato |
| Neurocrine Biosciences, INC. | $277.63 | 2022-2025 | Ingrezza |
| Tris Pharma INC | $211.50 | 2022-2025 | Dyanavel Xr |
| Lundbeck LLC | $209.69 | 2022-2025 | Rexulti, Brintellix |
| Sunovion Pharmaceuticals INC. | $147.00 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.70 | 2022-2025 | Trintellix |
| Alpha Cognition USA, INC. | $102.65 | 2025 | Zunveyl |
| Acadia Pharmaceuticals INC | $64.90 | 2024-2025 | Nuplazid |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $56.17 | 2022-2024 | Jornay Pm |
| Neos Therapeutics, Lp | $53.83 | 2022-2024 | Adzenys Xr-Odt |
| Bioxcel Therapeutics, INC. | $52.71 | 2023 | Igalmi |
| Collegium Pharmaceutical, INC. | $46.67 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $42.38 | 2023 | Xelstrym, Secuado |
| Corium, LLC | $40.68 | 2022-2025 | Azstarys |
| Eisai INC. | $18.03 | 2022 | |
| Owp Pharmaceuticals, INC. | $17.12 | 2024 | Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Ferrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.